![Author ORCID: We display the ORCID iD icon alongside authors names on our website to acknowledge that the ORCiD has been authenticated when entered by the user. To view the users ORCiD record click the icon. [opens in a new tab]](https://chemrxiv.org/engage/assets/public/chemrxiv/images/logos/orcid.png)
Abstract
COVID-19 is caused by severe respiratory syndrome –coronavirus 2 (SARS CoV-2). This has been declared as a global pandemic by World Health Organization (WHO). Currently only supportive care is available for treatment of patients. However availability of direct therapeutic approaches would greatly benefit the patient care and reduce death among COVID- 19 patients. Repurposing of approved drugs against COVID-19 would be a faster method to identify direct therapeutics against COVID-19. This study describes screening and identification of Amodiaquine a known antimalarial as COVID-19 Mpro inhibitor by pharmacophore modeling and molecular docking. Amodiaquine may be repurposed as COVID-19 drug after thorough clinical tests.
